DNA In-Vitro Life Science Protein 
XTalks
SEPTEMBER 30, 2020
The two studies were recently published online in the journal Science, both of which were led by Jean-Laurent Casanova, an infectious disease geneticist at Rockefeller University. Upon encountering a virally-infected cell, interferons trigger an immediate local response, causing infected cells to produce proteins that fight the virus.
XTalks
AUGUST 12, 2020
Despite the effectiveness of anti-retroviral therapy (ART) in significantly improving health, quality of life and reducing mortality among HIV-positive individuals, new research shows that persistent infections may be due to the ability of the virus to take refuge in distinct subsets of immune T cells.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
NOVEMBER 7, 2022
Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. These tumor-derived entities are used to derive genomic and proteomic data. The same webinar held a Q&A session with Dr. Bahassi and two other experts from Medpace, Dr. Lyon L.
Pharmaceutical Technology
NOVEMBER 22, 2022
The mission was first put forward during the UK’s G7 Presidency of June 2021, with support from representatives of the life sciences industry. Messenger RNA vaccines contain nucleic acids that code for a specific protein, or target antigen, related to a virus or disease. Single- and multi-nation funding opportunities flooded in.
XTalks
MAY 12, 2022
The life of the transplant recipient crucially depends on the early detection of any signs of organ or graft rejection. This diagnostic assay works on the principle of in vitro nucleic acid amplification using real-time transcription-mediated amplification (TMA) technology. Cytomegalovirus (CMV) Infection in Transplant Recipients.
Drug Discovery World
FEBRUARY 27, 2023
“We’re transforming drug discovery, and it all begins in the lab where researchers can leverage multimode plate reader technology like the EnVision Nexus system to increase R&D productivity at nearly every stage of their process,” said PerkinElmer Senior Vice President of Life Sciences Alan Fletcher. “By
Drug Discovery World
OCTOBER 14, 2022
Arndt Aspe r ger , Senior Applications Scientist , Bruker Daltonics and M ei ke Hamester , Vice President Label-Free Technologies , Bruker Daltonics , examine how challenges in mass spectrometry for high-throughput screening can be overcome using a label-free approach. . The rapid evolution of HTS to meet industry demand .
Expert insights. Personalized for you.
135 
Let's personalize your content